Introduction

Vancomycin and piperacillin-tazobactam are commonly combined for broad-spectrum antibiotic coverage including MRSA and Pseudomonas in hospitalized patients. Acute kidney injury, often manifesting as acute tubular necrosis, is a known complication of vancomycin therapy, especially at higher doses and with co-administration of nephrotoxic agents. Recent data challenge the clinical significance of this association.

Key Background Points

  • Vancomycin + piperacillin-tazobactam provides broad-spectrum coverage including MRSA and Pseudomonas
  • AKI (often acute tubular necrosis) is a known vancomycin complication, especially with higher doses and co-nephrotoxins
  • Piperacillin-tazobactam alone has minimal nephrotoxicity (<1%); usually due to acute interstitial nephritis
  • Reported AKI rates vary based on AKI definition and target population
  • Both drugs affect OAT1/3 transporters in the kidney, crucial for creatinine clearance — especially significant in CKD patients

Pharmacology Comparison

Parameter Vancomycin Piperacillin-tazobactam
Dose

Depends on infection and PK/PD target

General: 15–20 mg/kg IV Q8–12H for systemic infections

Standard: 3.375 g IV Q6H over 30 min

Anti-pseudomonal: 4.5 g IV Q6–8H over 30 min

Extended infusion: 4.5 g IV then 3.375–4.5 g over 4 hours Q8H
Administration
Administer IV over ≥60 minutes at concentrations ≤5 mg/mL to reduce risk of vancomycin infusion reaction Standard: infuse over 30 min. Extended: loading dose over 30 min, start maintenance 4 hours later infused over 4 hours
PK/PD

Negligible oral bioavailability

T1/2 = 4–6 hours

Renally eliminated (40–100% unchanged)

AUC/MIC ≥400 µg/mL target; trough-guided regimens exceed target AUC in 60% of adults10

T1/2 = 0.7–1.2 hours

Renally eliminated (80% unchanged)

Dose adjust at CrCl <40 mL/min

T>MIC dependent; prolonged infusions enhance efficacy
Adverse Effects
Nephrotoxicity Ototoxicity Infusion Reaction
GI upset Headache Rash/Pruritis
Drug Interactions

Substrate of OAT1/3 +/- Inducer of OAT1/3

↑ nephrotoxicity: aminoglycosides, aspirin

Piperacillin: substrate and inhibitor of OAT1/3

Tazobactam: substrate of OAT1/3

Interactions: Probenecid (↑ pip-tazo), Methotrexate (↑ MTX)
Compatibility

OK: Dextrose, NS, LR

Avoid: Lipid emulsion

LR: only EDTA formulation for Y-site

Avoid: NaHCO3, blood products, albumin hydrolysates

Clinical Pearl — OAT1/3 Transporters

Both vancomycin and piperacillin-tazobactam interact with organic anion transporters (OAT1/3) in the kidney. Piperacillin inhibits OAT1/3, which may impair creatinine secretion and elevate serum creatinine without true tubular damage — potentially explaining the “pseudotoxicity” signal seen in the literature. Meropenem is also a substrate of OAT1/3 but not an inhibitor.

Overview of Key Evidence

RIFLE, AKIN, and KDIGO definitions of AKI are based upon increases in serum creatinine or decreases in urine output.

Author / Year Design (n) Intervention AKI Definition Key Findings
Sanz et al., 200213 Prospective RCT
n=969 		Amikacin + cefepime vs. amikacin + pip-tazo ↑ SCr ≥50% from baseline No difference

No difference in severe nephrotoxicity between groups
Karino et al., 201615 Retro Cohort
n=320 		Vanc + pip-tazo standard vs. extended infusion RIFLE, AKIN, Vanc consensus AKI in 33%

Extended infusion did not increase AKI risk; highest incidence at day 5
Hammond et al., 201716 Meta-analysis
14 studies, n=3,549 		Vanc + pip-tazo vs. vanc + any beta-lactam or vanc alone RIFLE, AKIN, ↑SCr ≥100% or >0.5 mg/dL aOR 3.11 (1.77–5.47)

Greater association with AKI; highest in ICU patients (OR 3.83)
Rutter et al., 201717 Retro Cohort
n=4,103 		Vanc + pip-tazo vs. vanc + cefepime RIFLE 2.18x more AKI

95% CI 1.64–2.94; vanc doses 3–4 g daily
Peyko et al., 201718 Prospective Obs
n=85 		Vanc + pip-tazo vs. vanc + cefepime or meropenem KDIGO 37.3% vs 7.7%

Higher AKI with vanc + pip-tazo (P = .005)
Rutter & Burgess, 201719 Retro Cohort
n=2,448 		Vanc + pip-tazo vs. vanc + amp-sulbactam RIFLE aOR 1.77 (1.26–2.46)

No increased AKI with vanc + amp-sulbactam; similar AKI for pip-tazo and amp-sulbactam without vanc
Jeon et al., 201720 Retro Cohort
n=5,335 		Vanc + pip-tazo vs. vanc + cefepime ↑SCr ≥0.3 mg/dL or ≥50% aHR 1.25 (1.11–1.42)

Higher AKI risk with vanc + pip-tazo vs cefepime
Miano et al., 202221 Prospective Obs
Observational 		Vanc + pip-tazo vs. vanc + cefepime ≥48 hrs ↑SCr vs. ↑Cystatin C vs. ↑BUN
SCr-defined AKI only

↑ SCr-defined AKI but no change in cystatin C, BUN, or AKI outcomes (dialysis/mortality) — indicates pseudotoxicity
Qian et al., 2023 (ACORN)23 RCT
n=2,511 		Vanc + pip-tazo vs. vanc + cefepime KDIGO: ↑SCr ≥0.3 mg/dL or ≥50%
No significant difference

Highest stage AKI or death not significantly different; MAKE at day 14 did not differ (10.2% vs 8.8%); ~77% concurrently received vanc

Clinical Conclusions

Bottom Line

Despite >50 studies linking vancomycin + piperacillin-tazobactam with AKI, some experts report that the true renal risk is likely minimal. Recent RCT data (ACORN) and biomarker studies suggest the observed creatinine-defined AKI may represent pseudotoxicity rather than true nephrotoxicity.

Since 2011, evidence indicates combined vancomycin + piperacillin-tazobactam may be nephrotoxic. However, most studies were retrospective, defining nephrotoxicity by creatinine-based AKI.

Recent data show this AKI definition does not align with severe AKI outcomes (hemodialysis/mortality). Non-tubular secretion biomarkers (Cystatin C, BUN) did not show the same AKI increase.

Despite >50 studies linking the drug combo with AKI, some experts report true renal risk is likely minimal.

In emergencies, timely antibiotic use is vital; nephrotoxicity concerns should not delay this combination, especially for short-term use.

Full Reference List

  1. Micromedex [Electronic version]. Greenwood Village, CO: Truven Health Analytics. Retrieved October 4, 2023.
  2. Vancomycin Hydrochloride [package insert]. Rockford, IL: Mylan Institutional LLC; Jul 2018.
  3. Blair M, et al. Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review. Am J Nephrol. 2021;52(2):85-97.
  4. Pill MW, et al. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy. 1997;17(1):166-9.
  5. Li H, et al. Changes of renal transporters in the kinetic process of VCM-induced nephrotoxicity in mice. Toxicol Res (Camb). 2021;10(4):687-695.
  6. Giuliano CA, et al. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. Pharmacotherapy. 2016;36(12):1217-1228.
  7. Boucher H. Piperacillin-tazobactam. Sanford Guide Web Edition. 2023.
  8. Yang S, et al. Piperacillin enhances the inhibitory effect of tazobactam on beta-lactamase through inhibition of OAT1/3 in rats. Asian J Pharm Sci. 2019;14(6):677-686.
  9. Landersdorfer CB, et al. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol. 2008;66(5):648-59.
  10. Neely MN, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309-16.
  11. Alvarez-Arango S, et al. Vancomycin Infusion Reaction — Moving beyond “Red Man Syndrome.” N Engl J Med. 2021;384(14):1283-1286.
  12. Vallon V, et al. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol. 2012;302(10):F1293-9.
  13. Sanz MA, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia. J Antimicrob Chemother. 2002;50(1):79-88.
  14. Watkins RR, Deresinski S. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy. Clin Infect Dis. 2017;65(12):2137-2143.
  15. Karino S, et al. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam. Antimicrob Agents Chemother. 2016;60(6):3743-50.
  16. Hammond DA, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis. 2017;64(5):666-674.
  17. Rutter WC, et al. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrob Agents Chemother. 2017;61(2):e02089-16.
  18. Peyko V, et al. Prospective Comparison of Acute Kidney Injury During Treatment With Piperacillin-Tazobactam and Vancomycin vs Cefepime or Meropenem and Vancomycin. J Pharm Pract. 2017;30(2):209-213.
  19. Rutter WC, Burgess DS. Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations. Pharmacotherapy. 2017;37(5):593-598.
  20. Jeon N, et al. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy. Int J Antimicrob Agents. 2017;50(1):63-67.
  21. Miano TA, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults. Intensive Care Med. 2022;48(9):1144-1155.
  22. Evans L, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247.
  23. Qian ET, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA. 2023;330(16):1557-1567.
Tags: Infectious Disease Acute Kidney Injury Vancomycin Zosyn Pharmacy Friday Pearls

Never Miss a Pearl

Get Pharmacy Pearls delivered weekly

Join 3,000+ pharmacists who receive curated clinical insights every Friday.

Start Free Trial